HIRIP3

Summary

HIRIP3 (HIRA interacting protein 3, HGNC:4917) is a protein-coding gene on chromosome 16p11.2, encoding HIRA-interacting protein 3 (Q9BW71). Histone chaperone that carries a H2A-H2B histone complex and facilitates its deposition onto chromatin.

The HIRA protein shares sequence similarity with Hir1p and Hir2p, the two corepressors of histone gene transcription characterized in the yeast, Saccharomyces cerevisiae. The structural features of the HIRA protein suggest that it may function as part of a multiprotein complex. Several cDNAs encoding HIRA-interacting proteins, or HIRIPs, have been identified. In vitro, the protein encoded by this gene binds HIRA, as well as H2B and H3 core histones, indicating that a complex containing HIRA-HIRIP3 could function in some aspects of chromatin and histone metabolism. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.

Source: NCBI Gene 8479 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 108 total — 1 likely-pathogenic
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_003609

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4917
Approved symbol	HIRIP3
Name	HIRA interacting protein 3
Location	16p11.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000149929
Ensembl biotype	protein_coding
OMIM	603365
Entrez	8479

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 12 protein_coding, 4 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000279392, ENST00000563053, ENST00000563680, ENST00000564026, ENST00000565996, ENST00000566471, ENST00000568880, ENST00000873668, ENST00000873669, ENST00000873670, ENST00000873671, ENST00000873672, ENST00000873673, ENST00000918288, ENST00000948388, ENST00000948389, ENST00000948390

RefSeq mRNA: 2 — MANE Select: NM_003609 NM_001197323, NM_003609

CCDS: CCDS10664, CCDS58449

Canonical transcript exons

ENST00000279392 — 7 exons

Exon	Start	End
ENSE00000993026	29993906	29994843
ENSE00002608832	29995541	29995617
ENSE00002628577	29992330	29993370
ENSE00003546176	29995103	29995217
ENSE00003603199	29995343	29995463
ENSE00003626250	29993640	29993808
ENSE00003668554	29993459	29993557

Expression profiles

Bgee: expression breadth ubiquitous, 278 present calls, max score 94.25.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.3504 / max 315.7795, expressed in 1718 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
156981	4.5672	1375
156983	4.5510	1537
156982	0.5175	316
156984	0.4923	219
156980	0.2224	86

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	94.25	gold quality
left testis	UBERON:0004533	93.77	gold quality
right testis	UBERON:0004534	93.58	gold quality
testis	UBERON:0000473	91.64	gold quality
ganglionic eminence	UBERON:0004023	91.61	gold quality
ventricular zone	UBERON:0003053	91.47	gold quality
apex of heart	UBERON:0002098	91.10	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	90.82	gold quality
spinal cord	UBERON:0002240	90.07	gold quality
secondary oocyte	CL:0000655	89.67	gold quality
gastrocnemius	UBERON:0001388	89.59	gold quality
hindlimb stylopod muscle	UBERON:0004252	89.47	gold quality
embryo	UBERON:0000922	89.42	gold quality
muscle of leg	UBERON:0001383	89.06	gold quality
type B pancreatic cell	CL:0000169	88.90	gold quality
gluteal muscle	UBERON:0002000	88.43	gold quality
cerebellar hemisphere	UBERON:0002245	88.39	gold quality
prefrontal cortex	UBERON:0000451	88.33	gold quality
cerebellar cortex	UBERON:0002129	88.33	gold quality
right hemisphere of cerebellum	UBERON:0014890	88.32	gold quality
lateral globus pallidus	UBERON:0002476	88.20	silver quality
amygdala	UBERON:0001876	88.01	gold quality
lower esophagus muscularis layer	UBERON:0035833	87.73	gold quality
lower esophagus	UBERON:0013473	87.69	gold quality
cerebellum	UBERON:0002037	87.68	gold quality
putamen	UBERON:0001874	87.63	gold quality
muscle organ	UBERON:0001630	87.60	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	87.46	gold quality
heart left ventricle	UBERON:0002084	87.40	gold quality
triceps brachii	UBERON:0001509	87.39	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.67

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

40 targeting HIRIP3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-6744-5P	99.93	66.82	748
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-1251-3P	99.64	67.21	1408
HSA-MIR-3975	99.62	65.97	697
HSA-MIR-3136-3P	99.57	66.59	781
HSA-MIR-7155-3P	99.57	66.48	794
HSA-MIR-4276	99.56	67.66	2514
HSA-MIR-4687-3P	99.48	66.41	968
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-942-5P	99.41	68.40	1977
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-4667-3P	99.26	65.45	1608
HSA-MIR-7974	99.24	65.48	1137
HSA-MIR-7854-3P	99.08	66.26	1117
HSA-MIR-625-5P	99.02	68.64	2031
HSA-MIR-361-5P	98.95	70.16	1340
HSA-MIR-3928-5P	98.50	67.48	980
HSA-MIR-6806-3P	98.50	67.31	980
HSA-MIR-581	98.39	67.42	835
HSA-MIR-4664-5P	98.17	65.07	1020
HSA-MIR-4443	98.02	66.25	1928
HSA-MIR-924	97.78	66.21	681
HSA-MIR-483-3P	97.77	64.95	731
HSA-MIR-4675	97.69	64.82	774
HSA-MIR-4741	97.69	64.14	883

Literature-anchored findings (GeneRIF, showing 2)

• HIRIP3 can be phosphorylated in vitro by a recombinant form of the serine-threonine kinase CK2. Moreover, HIRIP3 protein was found to co-purify with a CK2 activity. (PMID:17391060)
• Identification and Characterization of HIRIP3 as a Histone H2A Chaperone. (PMID:38334665)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	hirip3	ENSDARG00000027749
mus_musculus	Hirip3	ENSMUSG00000042606
rattus_norvegicus	Hirip3	ENSRNOG00000029061

Protein

Protein identifiers

HIRA-interacting protein 3 — Q9BW71 (reviewed: Q9BW71)

All UniProt accessions (1): Q9BW71

UniProt curated annotations — full annotation on UniProt →

Function. Histone chaperone that carries a H2A-H2B histone complex and facilitates its deposition onto chromatin.

Subunit / interactions. Interacts (via C-terminus) with histone H2A-H2B dimers; the interaction is direct. Interacts with HIRA. Interacts with CK2.

Subcellular location. Nucleus.

Tissue specificity. Widely expressed. Isoform 1 is predominant in skeletal muscle. Isoform 2 is predominant in liver and heart.

Post-translational modifications. Phosphorylated by CK2.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9BW71-1	1	yes
Q9BW71-2	2
Q9BW71-3	3

RefSeq proteins (2): NP_001184252, NP_003600* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019098	Histone_chaperone_domain_CHZ	Domain
IPR037647	HIRIP3	Family

Pfam: PF09649

UniProt features (50 total): modified residue 30, compositionally biased region 10, region of interest 3, splice variant 3, sequence variant 2, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BW71-F1	60.04	0.21

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (30): 27, 84, 87, 98, 100, 125, 142, 143, 159, 160, 196, 199, 223, 227, 289, 291, 330, 332, 333, 357 …

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 143 (showing top): GGAMTNNNNNTCCY_UNKNOWN, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, chr16p11, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, IVANOVA_HEMATOPOIESIS_STEM_CELL_SHORT_TERM, FISCHER_DREAM_TARGETS, ACTWSNACTNY_UNKNOWN, GOCC_NUCLEOLUS, SCGGAAGY_ELK1_02, MULLIGHAN_MLL_SIGNATURE_1_UP, MGGAAGTG_GABP_B, NAKAMURA_METASTASIS_MODEL_UP, CASORELLI_ACUTE_PROMYELOCYTIC_LEUKEMIA_DN, GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_UP, PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_7

GO Biological Process (1): chromatin organization (GO:0006325)

GO Molecular Function (2): H2A-H2B histone complex chaperone activity (GO:0000511), protein binding (GO:0005515)

GO Cellular Component (3): nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nuclear lumen	2
cellular component organization	1
histone chaperone activity	1
binding	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

614 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
HIRIP3	HIRA	P54198	816
HIRIP3	H2BC21	Q16778	760
HIRIP3	SEZ6L2	Q6UXD5	703
HIRIP3	DOC2A	Q14183	696
HIRIP3	ASPHD1	Q5U4P2	688
HIRIP3	KIF22	Q14807	679
HIRIP3	PAGR1	Q9BTK6	676
HIRIP3	C16orf54	Q6UWD8	664
HIRIP3	KCTD13	Q8WZ19	643
HIRIP3	YPEL3	P61236	640
HIRIP3	INO80E	Q8NBZ0	627
HIRIP3	TMEM219	Q86XT9	605
HIRIP3	FIMP1	Q96LL3	602
HIRIP3	TAOK2	Q9UL54	602
HIRIP3	PPP4C	P33172	601

IntAct

47 interactions, top by confidence:

A	B	Type	Score
CSNK2A2	EIF3J	psi-mi:“MI:0914”(association)	0.790
HIRIP3	CSNK2B	psi-mi:“MI:0914”(association)	0.730
HIRIP3	AMPD2	psi-mi:“MI:0915”(physical association)	0.710
ASF1B	HAT1	psi-mi:“MI:0914”(association)	0.640
AMPD2	SDC2	psi-mi:“MI:0914”(association)	0.640
CSNK2A2	PES1	psi-mi:“MI:0914”(association)	0.640
HIRIP3	SGK2	psi-mi:“MI:0915”(physical association)	0.560
HTT	HIRIP3	psi-mi:“MI:0915”(physical association)	0.560
ENG	HIRIP3	psi-mi:“MI:0407”(direct interaction)	0.440
HIRIP3	SRPK2	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
SRPK1	HIRIP3	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
HIRIP3	VDAC3	psi-mi:“MI:0915”(physical association)	0.400
HIRIP3	H2BC9	psi-mi:“MI:0915”(physical association)	0.400
HIRIP3	H2BC12L	psi-mi:“MI:0915”(physical association)	0.400
HIRIP3	H1-4	psi-mi:“MI:0915”(physical association)	0.400
HIRIP3	PDIA3	psi-mi:“MI:0915”(physical association)	0.400
CSNK2A1	MYO1B	psi-mi:“MI:0914”(association)	0.350
TMPO		psi-mi:“MI:0914”(association)	0.350
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
HIRIP3	H2AX	psi-mi:“MI:0914”(association)	0.350
RYBP	PIPSL	psi-mi:“MI:0914”(association)	0.350
CSNK2A2	CNOT1	psi-mi:“MI:0914”(association)	0.350
CSNK2A1	EIF3F	psi-mi:“MI:0914”(association)	0.350
IQCB1	PCP4L1	psi-mi:“MI:0914”(association)	0.350

BioGRID (117): HIRIP3 (Affinity Capture-MS), HIRIP3 (Affinity Capture-MS), HIRIP3 (Co-fractionation), RPL8 (Co-fractionation), HIRIP3 (Proximity Label-MS), HIRIP3 (Affinity Capture-MS), HIRIP3 (Affinity Capture-MS), HIRIP3 (Affinity Capture-MS), HIRIP3 (Affinity Capture-MS), HIRIP3 (Affinity Capture-MS), HIRA (Reconstituted Complex), HIRIP3 (Affinity Capture-MS), HIRIP3 (Two-hybrid), HIRIP3 (Affinity Capture-MS), HIRIP3 (Proximity Label-MS)

ESM2 similar proteins: A0P8Z5, A2AJT4, A6NNA2, A7MD48, F1LR10, O88573, P0CB65, P51825, P51826, P51827, Q14241, Q2KJH5, Q2T9Y0, Q569Z6, Q5BJ39, Q5M7V8, Q5PPJ2, Q5RD75, Q5T6C5, Q5VUA4, Q63187, Q6QZN6, Q6ZPR1, Q80WV7, Q80Z37, Q8BKA3, Q8BM65, Q8BTI8, Q8BZX4, Q8CB77, Q8K019, Q8TF01, Q93075, Q96B23, Q96IZ7, Q96RL1, Q99PP2, Q9BW71, Q9DBU6, Q9ERQ3

Diamond homologs: Q8BLH7, Q9BW71

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 49 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Replacement of protamines by nucleosomes in the male pronucleus	5	34.9×	5e-05
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	5	18.8×	4e-04
CHD1 and CHD2 subfamily	5	13.9×	9e-04
NoRC negatively regulates rRNA expression	5	13.4×	9e-04
Activation of anterior HOX genes in hindbrain development during early embryogenesis	5	11.7×	1e-03

GO biological processes:

GO term	Partners	Fold	FDR
nucleosome assembly	7	21.9×	1e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

108 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	89
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1330157	GRCh37/hg19 16p11.2(chr16:29974415-30596982)x1	Likely pathogenic

SpliceAI

1096 predictions. Top by Δscore:

Variant	Effect	Δscore
16:29993366:CCGGC:C	acceptor_gain	1.0000
16:29993367:CGGC:C	acceptor_gain	1.0000
16:29993367:CGGCC:C	acceptor_gain	1.0000
16:29993368:GGC:G	acceptor_gain	1.0000
16:29993369:GC:G	acceptor_gain	1.0000
16:29993370:CC:C	acceptor_gain	1.0000
16:29993371:C:CC	acceptor_gain	1.0000
16:29993372:T:C	acceptor_loss	1.0000
16:29993453:CCTTA:C	donor_loss	1.0000
16:29993454:CTTA:C	donor_loss	1.0000
16:29993455:TTACC:T	donor_loss	1.0000
16:29993456:TA:T	donor_loss	1.0000
16:29993457:A:AC	donor_gain	1.0000
16:29993457:AC:A	donor_gain	1.0000
16:29993457:ACCCG:A	donor_loss	1.0000
16:29993458:C:CC	donor_gain	1.0000
16:29993458:CC:C	donor_gain	1.0000
16:29993638:AC:A	donor_gain	1.0000
16:29993639:CC:C	donor_gain	1.0000
16:29993639:CCCTT:C	donor_gain	1.0000
16:29993652:G:C	donor_gain	1.0000
16:29993657:T:TA	donor_gain	1.0000
16:29993681:A:AC	donor_gain	1.0000
16:29993681:AGG:A	donor_gain	1.0000
16:29993681:AGGCG:A	donor_gain	1.0000
16:29993682:G:C	donor_gain	1.0000
16:29993804:CCAGC:C	acceptor_gain	1.0000
16:29993805:CAGC:C	acceptor_gain	1.0000
16:29993805:CAGCC:C	acceptor_gain	1.0000
16:29993807:GC:G	acceptor_gain	1.0000

AlphaMissense

3652 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:29993660:A:G	L463P	0.998
16:29993672:A:T	L459H	0.998
16:29993758:C:A	K430N	0.998
16:29993758:C:G	K430N	0.998
16:29995576:G:C	F10L	0.997
16:29995576:G:T	F10L	0.997
16:29995578:A:G	F10L	0.997
16:29993672:A:G	L459P	0.996
16:29993750:A:T	I433N	0.996
16:29993762:A:G	L429P	0.995
16:29993254:A:G	W542R	0.994
16:29993254:A:T	W542R	0.994
16:29993660:A:T	L463Q	0.994
16:29993750:A:G	I433T	0.994
16:29993228:G:C	S550R	0.993
16:29993228:G:T	S550R	0.993
16:29993230:T:G	S550R	0.993
16:29993750:A:C	I433S	0.993
16:29993745:C:G	A435P	0.992
16:29993252:C:A	W542C	0.991
16:29993252:C:G	W542C	0.991
16:29995577:A:G	F10S	0.991
16:29993232:A:T	I549N	0.990
16:29993523:C:A	K481N	0.990
16:29993523:C:G	K481N	0.990
16:29993741:C:T	C436Y	0.990
16:29995356:A:G	L58P	0.990
16:29993473:A:G	I498T	0.989
16:29993488:A:G	L493S	0.989
16:29993645:A:G	M468T	0.989

dbSNP variants (sampled 300 via entrez): RS1000638423 (16:29994476 A>G), RS1001278787 (16:29998006 A>G), RS1001640977 (16:29995506 G>A), RS1002589261 (16:29991940 C>G), RS1003059588 (16:29995361 C>T), RS1003113623 (16:29995654 T>C), RS1003367469 (16:29996125 T>A,G), RS1004591487 (16:29996288 T>C), RS1005078146 (16:29995915 G>C), RS1005673423 (16:29997093 C>T), RS1006344812 (16:29992551 G>C), RS1006397241 (16:29992198 C>G,T), RS1006591970 (16:29994094 T>C), RS1006950842 (16:29994424 C>T), RS1007271169 (16:29997702 C>T)

Disease associations

OMIM: gene MIM:603365 | disease phenotypes: MIM:613444

GenCC curated gene-disease

Mondo (1): distal 16p11.2 microdeletion syndrome (MONDO:0013267)

Orphanet (1): Distal 16p11.2 microdeletion syndrome (Orphanet:261222)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST002539_82	Schizophrenia	5.000000e-11
GCST004521_236	Autism spectrum disorder or schizophrenia	4.000000e-10
GCST006803_23	Schizophrenia	6.000000e-13
GCST007293_15	Body fat distribution (arm fat ratio)	6.000000e-06
GCST007293_81	Body fat distribution (arm fat ratio)	4.000000e-08
GCST007611_22	Chronic obstructive pulmonary disease or high blood pressure (pleiotropy)	7.000000e-09
GCST010703_269	Brain morphology (MOSTest)	4.000000e-13

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004341	body fat distribution
EFO:0004346	neuroimaging measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5724673 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.12	Kd	75	nM	MOLIBRESIB
7.05	IC50	90	nM	MOLIBRESIB

PubChem BioAssay actives

2 with measured affinity, of 7 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2179241: Binding affinity against HIRIP3 (unknown origin) assessed as apparent dissociation constant incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	kd	0.0750	uM

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression, decreases expression, increases abundance	3
bisphenol A	affects cotreatment, increases expression, decreases expression	2
Valproic Acid	decreases expression, increases methylation	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
FR900359	affects phosphorylation	1
methylmercuric chloride	decreases expression	1
propionaldehyde	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
coumarin	affects phosphorylation	1
isobutyl alcohol	affects cotreatment, decreases expression, increases abundance	1
di-n-butylphosphoric acid	affects expression	1
trans-10,cis-12-conjugated linoleic acid	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Arsenic	increases abundance, increases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Caffeine	decreases phosphorylation	1
Calcitriol	decreases expression, affects cotreatment	1
Coumestrol	affects cotreatment, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Estradiol	increases expression	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1
Indomethacin	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
Methyl Methanesulfonate	increases expression	1
Polycyclic Aromatic Hydrocarbons	affects cotreatment, decreases expression, increases abundance	1
Potassium Dichromate	increases expression	1

ChEMBL screening assays

7 unique, capped per target: 7 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697735	Binding	Inhibition of HIRIP3 (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.